Drugs / INS062
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05887895 | May → Jul 2023 | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INS062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05887895 ↗ |
| Route | Subcutaneous | “Subjects were given HR20014, INS068, or INS062 injections subcutaneously once in three cycles.” NCT05887895 ↗ |